Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
  • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
  • A61L27/3633—Extracellular matrix [ECM]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
  • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
  • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2430/00—Materials or treatment for tissue regeneration
  • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

• the present invention relates to the identification and use of hematopoietic stem cells (HSC). More specifically the invention relates to the differentiation autologueous hematopoietic stem cells into myeloid lineages for reintroduction into the patient in addition to undifferentiated stem cells for the purpose of reconstituting both the defence and long- term engraftment.
• HSC hematopoietic stem cells
• Bone marrow (BM) transplantation is being increasingly used in humans as an effective therapy for an increasing number of diseases, including malignancies such as leukemias, lymphoma, myeloma and selected solid tumors as well as nonmalignant conditions such as severe aplastic anemias, immunologic deficiencies and inborn errors of metabolism.
• the objective of BM transplantation is to provide the host with a healthy stem cell population that will differentiate into mature blood cells that replace deficient or pathologic cell lineages.
• the source of the BM for transplantation may be autologous, syngeneic or allogeneic. Preferred are autologous BM or BM from HLA-matched siblings, but also BM from HLA-nomnatched donors is being used for transplantation.
• Hematopoietic stem cells are rare cells that have been identified in fetal bone marrow, umbilical cord blood, adult bone marrow, and peripheral blood, which are capable of differentiating into each of the myeloerythroid (red blood cells, granulocytes, monocytes), megakaryocyte (platelets) and lymphoid (T-cells, B-cells, and natural killer cells) lineages. In addition these cells are long-lived, and are capable of producing additional stem cells, a process termed self-renewal.
• Progenitor cells initially undergo commitment to lineage restricted progenitor cells, which can be assayed by their ability to form colonies in semisolid media. Progenitor cells are restricted in their ability to undergo multi-lineage differentiation and have lost their ability to self-renew. Progenitor cells eventually differentiate and mature into each of the functional elements of the blood. The lifelong maintenance of mature blood cells results from the proliferative activity of a small number of pluripotent hematopoietic stem cells that have a high , but perhaps limited , capacity for self- renewal. In culture, hematopoietic stem cells rapidly commit to differentiated cell types, which irreversibly predominate in the culture. This property, along with their relative scarcity in blood, presents challenges to the creation of long term, stable cultures of pluripotent hematopoietic stem cells.
• VLA-4 very late antigen 4
• VLA-5 very late antigen 4
• LFA-1 P2 integrin lymphocyte function-associated 1
• VLA-4 plays an especially important role in murine stem cell migration and hematopoiesis in vivo.
• Murine stem cells lacking P I integrins fail to colonize the fetal liver (Hirsh et al., 1996).
• BMT has the potential to treat a number of disorders, including cancer (lymphomas), hemoglobinopathies (sickle cell disease, thalassemia), soluble enzyme deficiencies, and autoimmune disorders.
• cancer lymphomas
• hemoglobinopathies thin cell disease, thalassemia
• the method of this invention comprises introducing a combination of autologous hematopoietic stem cells and myeloid lineage cells obtained by differentiating autologous hematopoietic stem cells into a recipient.
• the i nvention is also d i rected to a method for conducting autologous stem cell transplantation in a patient that is going to receive cytoreductive therapy, comprising: (1 ) obtaining hematopoietic stem cells (or hematopoietic progenitor cells) from a patient prior to cytoreductive therapy; (2) expanding the hematopoietic stem cells (or hematopoietic progenitor cells) ex vivo with an extracellular matrix extract of the present invention, to provide a cellular preparation comprising increased numbers of hematopoietic stem cells (or hematopoietic progenitor cells) as well as differentiated blood cell lineages, such as a myeloid lineage; and (3) administering the cellular preparation to the patient in conjunction with or following cytoreductive therapy.
• This method has shown to be superior for the purpose of reconstituting both the defence and long-term engraftment.
• Stem cells may be obtained from peripheral blood harvest or bone marrow explants.
• the inventive method optionally comprises a preliminary in vivo procedure comprising administering a recruitment growth factor to the patient to recruit hematopoietic progenitor cells into peripheral blood prior to their harvest, wherein the recruitment growth factor is selected from the group consisting of GM-CSF, SF, GCSF, IL-3, GM-CSF/IL-3 fusion proteins, and combinations thereof.
• the inventive method optionally comprises a subsequent in vivo procedure comprising ad min istering an engraftment growth factor to the patient following autologous transplantation of the cellular preparation to facilitate engraftment and augment proliferation of engrafted hematopoietic progenitor cells from the cellular preparation.
• the engraftment growth factor is selected from the group consisting of GM-CSF, IL-3, SF, GM-CSF/IL-3 fusion proteins and combinations thereof.
• the present invention further includes a progenitor cell expansion media comprising cell growth media, autologous serum, and a growth factor selected from the group consisting of SF, HL-I, IL-3, GM-CSF, GM-CSFAL-3 fusion proteins, and combinations thereof with the proviso that IL-1 must be used in combination with at least one other growth factor.
• a progenitor cell expansion media comprising cell growth media, autologous serum, and a growth factor selected from the group consisting of SF, HL-I, IL-3, GM-CSF, GM-CSFAL-3 fusion proteins, and combinations thereof with the proviso that IL-1 must be used in combination with at least one other growth factor.
• the invention includes methods of treating a mammal.
• a mammal is first identified, having a disorder characterized by an insufficient number of hematopoietic cells; a sample of hematopoietic stem cells is obtained from the mammal for an autologous transplant, the sample further including a subset of undifferentiated hematopoietic stem cells; the sample of hematopoietic cells is cultured in culture media comprising an extracellular matrix extract of the present invention and under conditions appropriate to cause proliferation of the undifferentiated hematopoietic cells; the undifferentiated hematopoietic cells are segregated from differentiated hematopoietic cells; and the segregated undifferentiated hematopoietic cells are cultured further, thereby causing further proliferation of the segregated undifferentiated hematopoietic cells.
• the mammal is provided with a suitable quantity of the cultured undifferentiated hematopoietic cells, and the cultured undifferentiated hematopoietic cells increase the number of hematopoietic cells in the mammal, thereby treating the disorder.
• Embodiments of the invention include open and closed systems.
• Disorders suitable for treatment include, for example but not limited to a cytopenia or an anemia such as those induced by cancer treatments, or a genetic defect resulting in aberrant levels of blood cells, or cancer, for example a graft versus tumor approach.
• cultures of undifferentiated hematopoietic stem cells with long-term repopulating potential are expanded prior to transplantation in the mammal.
• the invention includes a method for providing a cell population of undifferentiated human hematopoietic cells.
• a human bone marrow extracellular matrix extract and soluble factors obtainable by a method comprising the steps:
• the environment comprising extracellular matrix resembling the extracellular matrix of the human bone marrow is obtainable by isolating bone marrow from a mammal, preferably a pig, a cow, or a human.
• This bone marrow extracellular matrix extract may then be used to differentiate new stem cells of the bone marrow, or alternatively an extracellular matrix extract resembling the bone marrow extracellular matrix extract is used.
• a method for autologous hematopoietic cell transplantation in a patient comprising: i) removing hematopoietic stem cells from the patient; ii) optionally expanding the hematopoietic stem cells ex vivo with a growth factor selected from the group consisting of GM-CSF, SF, IL-3, IL- 1 , GM-CSF/IL-3 fusion proteins, and combinations thereof to provide a cellular preparation comprising an expanded population of hematopoietic progenitor cells; iii) contacting a fraction of the hematopoietic stem cells with a human based extract and soluble factors of the present invention or a decellularised form of the extracellular matrix resembling the extracellular matrix of the human bone m
• I n accordance with the above the present invention also provides a method for manufacturing mammalian, preferably human, bone marrow extracellular extracts and soluble factors ex vivo, wherein the composition of the extracts resembles the mammalian, preferably human, in vivo composition of the bone marrow.
• Such extracts are very suitable for the above mentioned differentiation of hematopoietic stem cells into hematopoietic progenitor cells.
• the extracellular matrix resembling the extracellular matrix of the bone marrow tissue may be of human or animal origin, such as equine, canine, porcine, bovine, and ovine sources; or rodent species, such as mouse or rat.
• an animal extracellular matrix extract may be used to induce the differentiation and thus stimulate the human stem cells to secrete an extracellular matrix of human origin.
• the human stem cells differentiate they will produce an extracellular matrix layer or body, which predominantly contains differentiated human cells along with the extracellular matrix produced by them-selves; thus, if the stem cells have been stimulated to differentiate in an extract of animal origin there will be no fractions of non-human material left in the produced extracellular matrix layer. Since the in vivo composition of the extracellular matrix is achieved when the stem cells are fully differentiated into the cells of the tissue of interest it is often necessary to cultivate the stem cells for generally at least 14 days. In any event the cells are assessed before harvesting the extracellular matrix; as a general rule at least 90% of the cells should be fully differentiated before preparing the extracellular matrix.
• the stem cells are only initially stimulated with the animal derived bone marrow extracellular matrix, thereafter the stimulated cells are carefully washed before they are cultured in a common growth medium; ii) the stem cells are stimulated with a human bone marrow extracellular matrix, and iii) the stem cells are stimulated with a "synthetic" extracellular matrix comprising growth and differentiation factors known to be (at least partially) responsible for the differentiation of stem cells into a given tissue cell type.
• Extracellular matrix and soluble factors of the bone marrow tissue can be used in vivo to induce hematopoietic progenitor cells in bone marrow to proliferate and to mobilize such hematopoietic progenitor cells into peripheral blood.
• Hematopoietic progenitor cells harvested from peripheral blood can be used for hematopoietic rescue therapy of patients treated with cytoreductive agents.
• the present invention involves ex vivo treatment of hematopoietic progenitor cells from peripheral blood or bone marrow with growth factors to increase their numbers prior to infusion or transplantation.
• growth factors can be used to facilitate engraftment and proliferation of transplanted hematopoietic progenitor cells following transplantation.
• Hematopoietic reconstitution of a patient undergoing cytoreductive therapy can reduce the incidence of infection and bleeding complications of patients treated with high doses of cytoreductive therapies, such as myelosuppressive cancer chemotherapeutic agents or high doses of radiotherapy.
• HSCs hematopoietic stem cells
• the terms “undifferentiated hematopoietic cell”, “undifferentiated cell”, “hematopoietic stem cell (HSC)”, and “primitive cell” are used interchangeably to describe a pluripotential hematopoietic stem cell that is capable of long term in viva expansion and repopulation when transplanted into a mammal. It has been established that the most primitive cell types express the cell surface antigen CD34, which is a transmembrane glycophosphoprotein thought to play an important role in stem and progenitor cell adhesion in BM. Cell populations expressing CD34 and lacking the CD38 antigen (i.e. CD34+CD38- cells) have been shown to display primitive cell potentials.
• the majority of SRCs can be found in the CD34+ CD38- cell fractions and not in the CD34+CD38+ populations, which are thought to contain more differentiated cell types.
• the CD34+CD38- phenotype has also been associated with an enrichment of cells having LTC-IC characteristics.
• the existence of murine and human CD34- HSCs that are capable of long- term multilineage repopulation illustrates that the CD34 antigen may itself be regulated independently of HSC potential and that CD34 expression itself is not a requisite HSC marker.
• Primitive cells have also been identified based on the expression of Thy-1 , a T- cell related marker. Thy-1 expression allows for the recovery of LTC- ICs from UCB, BM and human fetal liver mononuclear cells (MNCs) and accounts for all repopulating cells (Thy- 1.1 10) present in mouse BM.
• CD133 a transmembrane receptor glycoprotein has also been shown to coincide with the enrichment of early hematopoietic progenitors.
• CD34+CD133+ cell fractions isolated from UCB are highly enriched in primitive progenitors and SRCs that additionally have the capacity to engraft secondary recipients.
• vascular growth factor receptor 2 KDR
• the absence of specific antigens can also be used to characterize and isolate primitive hematopoietic stem cell populations.
• human CD34+ cells lacking HLA-DR 36 or CD45RA/CD71 identify primitive multipotential hematopoietic cells capable of self- renewal and differentiation into multiple hematopoietic lineages.
• isolating cells that lack markers associated with mature myeloid and lymphoid cells represents a method of enriching for primitive cell types.
• the term "differentiated hematopoietic cell”, “differentiated cell”, or “progenitor cell” refers to a lineage committed hematopoietic cell. These cells typically express one or more of the antigens CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and glycophorin A, and are termed lineage markers (Nn+). The detection of lin+ antigens indicates the loss of pluripotential properties and that the cell has become differentiated, or lineage committed. Accordingly, these fin+ antigens also provide the appropriate antigens for targeted separation of differentiated cells as described herein, and antibodies to these antigens are widely available for immunoseparation procedures.
• TGF transforming growth factor
• MIP macrophage inflammatory protein
• the removal of these cells may also provide a mechanism to enrich for cells that may secrete stimulatory factors.
• Usable methods that control and modulate the endogenous production of stimulatory and inhibitory factors thus overcome limitations of current HSC expansion systems.
• the HSCs generated as described herein can be used for a variety of clinical applications.
• the expanded HSCs can be transplanted for amelioration of cytopenia and anemia induced by radiotherapy or chemotherapy using anticancer drugs, in order to enhance or accelerate immune and hematopoietic recovery following intensive treatment.
• the invention can be used for prevention and treatment of infectious diseases associated with lymphopenia, such as the CD4+ T cell depletion seen with chronic HIV infection.
• the HSCs can be cultured with differentiating factors to produce specific blood cell types.
• HSCs produced using this invention can be induced to differentiate into cells of a desired population and function using known biological agents.
• the invention can generate "designer transplants" with a plurality of functions established to provide the greatest patient care.
• the HSCs can also be used in gene therapy, to express a transgene in a recipient subject, taking advantage of their reduced immunogenicity and pluripotential properties.
• the present invention provides for expanding stem or progenitor cells, particularly of the hematopoietic lineage.
• the process generally includes obtaining hematopoietic cells that are enriched for hematopoietic stem and progenitor cells, and introducing them into a suitable growth medium.
• the cells are maintained in culture and allowed to proliferate.
• Differentiated cells and endogenous growth factors are removed, either continuously during culture or intermittently during the culture process, for example, through performing media exchange on the cells remaining in culture, and by targeted separation and removal of differentiated cells.
• the remaining undifferentiated stem cells are cultured and allowed to proliferate further. Multiple cycles of culture and selection/media exchange are performed to expand the cells.
• differentiated cells in various phases of lineage commitment can be selected and propagated further in accordance with the invention.
• one or more hematopoietins can be added to the culture to force differentiation or lineage commitment. It is preferred that cell expansion and selection be performed in a completely controllable, environmentally closed-system, in accordance with FDA and other regulations governing the handling and processing of blood products, and to maintain sterility.
• the bioprocess disclosed herein can be practiced as an open system or as a closed system. Closed systems are generally sealed from the environment, and provide a more regulatable sterile microenvironment for the culture. Additional benefits to closed systems include increased safety for researchers and medical professionals in the handling of biological fluids. Current FDA and other administrative guidelines require closed systems for the handling and processing of blood cells and products designed to be used in humans, and are accordingly preferred. However, open systems exist for the expansion of hematopoietic stem cells, such as those disclosed herein, and for example US patents 5,674,750 and 5,925,567 (each incorporated herein by reference in their entirety) and other known systems can be modified in accordance with the teachings provided herein to produce a suitable open system bioprocess.
• the invention consists of one or more cell culture chambers, capable of receiving and containing a sample of cells.
• the cell culture chambers may be substantially rigid, for example, as in the case of a cell culture flask or dish, or may be semi-rigid, for example, as in the case of a cell culture bag.
• cell culture containers chambers
• Suitable materials are ones that can withstand a variety of sterilization techniques including autoclaving and gamma irradiation and, for those components which directly contact cells, should also be biologically inert.
• a currently preferred embodiment employs cell culture bags that are semi-permeable to oxygen gas and carbon dioxide gas, but substantially impermeable to water vapor and liquids such as cell culture media, thus ensuring no or little loss of growth medium during culture.
• Fluorinated ethylene polymers exemplify material suitable for this purpose.
• Other materials that are not gas permeable but meet the appropriate criteria include polypropylene, stainless steel and other medical grade materials, particularly polymers.
• the cell culture chambers may include one or more ports, replaceable caps or covers, self- sealing septa such as rubber stoppers, valves, or similar means that allow the user to add or remove materials from the chamber without substantial exposure of the interior of the bioprocess to the external environment.
• these mechanisms permit the cells, media and other components, such as antibodies and growth factors, to be introduced into the chamber, and permit removal of media, cells, endogenous soluble growth factors and the like, from the chamber, while maintaining an environmentally closed system.
• Vents, regulators or other ports for attaching external gas (e.g., oxygen or air) or liquid (e.g., culture media) sources, or for attaching pumps or pressure devices, may be provided.
• CFCs Colony forming cells
• LTC-ICs Long-term culture-initiating cells
• stromal cells which are composed of mesenchymal cells including fibroblasts, endothelial cells, adipocytes and osteogenic cells, produce a variety of soluble factors that support the long-term proliferation and maintenance of LTC-ICs.
• the sensitivity of this assay can be increased through the use of genetically engineered murine fibroblast (M2-1 OB4) cell lines that secrete factors known to enhance the detection I and maintenance of LTC-ICs.
• M2-1 OB4 genetically engineered murine fibroblast
• In vivo functional assays offer the best indication of the developmental potential of a hematopoietic cell population. This is because they directly test the potential for a stem cell population to contribute to the development or re development of a particular organ, tissue or system following intravenous injection.
• murine HSCs have been identified based on their ability to reconstitute hematopoiesis after transplantation into an immunocompromised and hematological ⁇ compromised host. Till and McCulloch first reported the existence of such a cell type when they injected syngeneic BM cells into irradiated mouse recipients and observed the formation of multi-lineage colonies in the spleen.
• Hematopoietins are a generic name given to hematopoietic growth factors (HGF) or hematopoietic cytokines, which act on cells of the hematopoietic system. These factors are active at all stages of development, and accordingly these hematopoietins will be removed from the bioprocess to prevent HSC differentiation.
• HGF hematopoietic growth factors
• cytokines hematopoietic cytokines
• Hematopoietic growth factors are produced by many different cell types including those not belonging to the hematopoietic system. These factors are either secreted or they exist in membrane-bound or matrix-associated forms. They may have different modes of action also, such as autocrine, paracrine, or juxtacrine growth control. Production of hematopoietic factors is regulated strictly, i.e., they are synthesized by activated cells under certain conditions rather than being produced constitutively all the time. Many observations point to the existence of an ordered hierarchy and a concerted action of factors involved in the development of the hematopoietic system.
• Cytokines interact with HSCs via three classes of transmembrane receptors; 1 ) those with intrinsic tvrosine kinase activity, 2) those that interact with the gpl30 subunit and 3) those that interact with Janus kineses (JAKs).
• JNKs Janus kineses
• FL flk2/flt3 ligand
• SCF stem cell factor
• IL-6 interleukin-6
• SIL-6R I L-6/soluble IL-6- receptor
• TPO thrombopoietin
• IL-3 IL-1 , IL-12, granulocyte- colony stimulating factor (G-CSF) and granulocyte- macrophage- colony stimulating factor (GM- CSF) 90-0.
• stroma-free cytokine supplemented cultures which contained IL-1 , IL-3, IL-6, G-CSF, GM-CSF and SCF, supported a significant expansion (66- fold) of colony forming unit- granulocyte-macrophage (CFU-GM) progenitor cells.
• Exemplary culture conditions for growing HSCs are given in the Examples, but generally in accordance with the invention, a sample of cells containing a subset of HSCs is first obtained then cultured. The cultured cells are then maintained for a growth period suitable for allowing proliferation to occur, which may include media exchanges to remove soluble growth factors, after which time the HSCs are segregated from the other differentiated cells. The HSCs are then allowed to proliferate again as described . The segregation of differentiated cells can be performed again if necessary. At the end of the culture period the expanded HSCs can be preserved by freezing after addition of, for example glycerin, DMSO or a suitable cryopreservative, or used directly in a therapeutic procedure. It is important to note that the above steps can be performed with the entire bioprocess apparatus assembled or in separate parts in which cell culture is carried out independent of cell segregation.
• Clinical uses for HSCs include, for example, the therapeutic treatment of blood cancers treatment of anemia, treatment of hereditary blood disorders, replenishment of blood cells following high dose radiation and chemotherapy in the treatment of cancer, graft-versus- tumor treatment of cancer, treatment of autoimmune disorders, and in gene therapy approaches.
• a patient's own cancerous hematopoietic cells are first destroyed by high dose radiation and chemotherapy.
• the patient provides the source of transplantable HSCs, which are isolated and expanded according to the methods provided herein.
• the transplant of undifferentiated cells provides for long term repopulation of the blood of the recipient.
• Non-cancerous blood disorders amenable to treatment by HSC therapy include aplastic and other types of anemia.
• the transplant of undifferentiated cells provides for long term repopulation of the blood of the recipient.
• UCB multiple studies have; demonstrated that cell dose is an important determinant of patient survival in stem cell transplantation scenarios.
• a control group of 5 mice were ablated by Busilvex but did not receive any IV injection of CB MNCs.
• Two groups of 5 mice each received 3M CB MNCs that were put in culture for 7 days in the presence or absence of X.
• the % of engraftment increased from 3% in the mice without X to more than 10% in the mice with X.
• the difference was statistically significant between the 2 groups of mice (P ⁇ 0.05).
• the increase in engraftment is also shown with the human pan leukocytic (CD45), B lymphocytes (CD19) and myeloid cells (CD33) markers.
• a control group of 3 mice were ablated by Busilvex but did not receive any IV injection of CB MNCs.
• Two groups of 3 mice each received 4M CB MNCs that were put in culture for 7 days in the presence or absence of X.
• the % of engraftment was assessed at 3 weeks, instead of 6 weeks, in order to assess immature erythroblasts and erythroid differentiation. As appears from FIG. 3 the engraftment increased from 11 % in the mice without X to 18% in the mice with X.
• the increase in engraftment was due mainly to increase in the numbers of immature erythroblasts (CD45-CD36+, heavy gray).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Urology & Nephrology (AREA)
• Epidemiology (AREA)
• Transplantation (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Dermatology (AREA)
• Botany (AREA)
• Zoology (AREA)
• Hematology (AREA)
• Molecular Biology (AREA)
• Cell Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Developmental Biology & Embryology (AREA)
• Biophysics (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oncology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42556414

Family Applications (1)

Country Status (5)

Families Citing this family (3)

Citations (6)

Family Cites Families (10)

• 2010
  • 2010-06-18 JP JP2012515517A patent/JP2012533519A/ja active Pending
  • 2010-06-18 WO PCT/EP2010/058675 patent/WO2010146177A1/en not_active Ceased
  • 2010-06-18 CN CN2010800267188A patent/CN102802686A/zh active Pending
  • 2010-06-18 EP EP10724868.4A patent/EP2442837B1/en not_active Not-in-force
  • 2010-06-18 US US13/320,872 patent/US20120065620A1/en not_active Abandoned

Patent Citations (6)

Non-Patent Citations (9)

Also Published As

Similar Documents

Legal Events